PT  - JOURNAL ARTICLE
AU  - Gerschutz, Gregory P.
AU  - Bhatt, Deepak L.
TI  - The CURE trial: Using clopidogrel in acute coronary syndromes without ST-segment elevation
DP  - 2002 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 377--385
VI  - 69
IP  - 5
4099  - http://www.ccjm.org/content/69/5/377.short
4100  - http://www.ccjm.org/content/69/5/377.full
SO  - Cleve Clin J Med2002 May 01; 69
AB  - In a large, randomized, placebo-controlled trial in centers that use a conservative approach to acute coronary syndromes, the antiplatelet drug clopidogrel (Plavix) decreased the rate of the combined end point of cardiovascular death, nonfatal myocardial infarction, or stroke by 20% in patients presenting with acute coronary syndromes without ST-segment elevation. The benefit was at the cost of an increase in bleeding, however. This strategy may need to be tailored in centers that use a more aggressive treatment strategy of early angiography and revascularization.